News

CrystEngComm celebrates the CSD in a special issue

The journal CrystEngComm has published a special issue to mark the Cambridge Structural Database (CSD) reaching 1 million structures, with 33 papers that highlight the breadth of applications made possible with this data.

The Royal Society of Chemistry journal CrystEngComm has published new research on all aspects in the design and understanding of solid-state and crystalline materials since 1999. They publish work covering a wide range of chemistries, but all involve the use of a design or optimisation strategy to develop a deeper understanding of the structures.

Employers responsibility to report COVID cases

Under RIDDOR (a health and safety regulation) employers now have a duty to report cases where employees have contracted COVID as a result of direct exposure due to work activities. Three specific circumstances have been identified: 1) “An accident or incident at work has, or could have, led to the release or escape of coronavirus”, 2) “A worker has been diagnosed with COVID-19 attributed to an occupational exposure to coronavirus.” 3) A worker dies as a result of occupational exposure to coronavirus.

Queen Mary University of London Researchers discover new therapy for osteoarthritis!

Prof Dell’ Accio and Dr Suzanne Eldridge from Queen Mary University of London have discovered a new therapeutic treatment for osteochondral defects shown to regenerate the cartilage and provide rapid, long-term pain relief.

These findings have been published in Science of Translational Medicine https://stm.sciencemag.org/content/12/559/eaax9086 and featured widely in the media https://sciencetm.altmetric.com/details/89347825#score.

New report shows 10% of UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst

A report released today by BioBeat showcasing the 30 top female leaders in the UK bioscience sector has named three people from organisations based at Stevenage Bioscience Catalyst (SBC), totalling 10% of the list.

The three mentioned leaders based at SBC are Shree Patel from Achilles Therapeutics, Nicole Mathon from LifeArc and Bakul Gupta from ImmTune Therapies.

Boyds strengthens regulatory affairs team with the appointment of experienced toxicologist

Leading pharmaceutical and biotech product development consultancy Boyds has added to its regulatory team with the appointment of experienced toxicologist, Dr Geoffrey Rose in response to the continued increase in demand for its dedicated regulatory services.

With more than 20 years’ regulatory experience across the full clinical product lifecycle, regulatory toxicologist Geoffrey joins Boyds as Director of Regulatory Affairs.

Congenica Completes $50m Series C Funding Round to Advance Clinical Genomic Analysis Software and Data Platform

New Funds to Drive Further Commercialisation of Rare and Inherited Cancer Applications and Expansion into Oncology, Wellness and Pharma Collaborations

Cambridge, United Kingdom – 9 November 2020 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, is pleased to announce the completion of its Series C funding round, raising US$50m/£39m.

Biocair and Roylance Pharma partner to provide end-to-end logistics services

Biocair, a global logistics company dedicated to the life sciences, has partnered with Roylance Pharma to deliver fully integrated transportation and storage services for temperature-controlled pharmaceutical and biological materials.

Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability

PhoreMost’s SITESEEKER^® platform will identify active peptides to be deployed within Oxford Biomedica’s LentiVector^® delivery system

APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery

- Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431

- Inhibitors discovered at Domainex via virtual and fragment screening

Vienna, Austria and Saffron Waldon, UK, 9th November 2020 / Sciad Newswire / APEIRON Biologics AG, a privately-held biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex Ltd to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery.

November eNews 2020

Find out what we're up to in this month's edition of eNews here.

My Account